Pause Video

Our Product Development Pipeline

Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.

CendR Platform® Programs

The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.

Indication Pre Clinical Phase 1 Phase 2 Phase 3

Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
Phase 2
Gemcitabine/nab-paclitaxel + LSTA1 (China)
Gemcitabine/nab-paclitaxel + LSTA1 (China)
Phase 1
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
Phase 1

Indication: Pancreatic, Colon, and Appendiceal Cancers

LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
Pancreatic, Colon, and Appendiceal Cancers
LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
Phase 1

Indication: Various Solid Tumors

SoC with LSTA1 or placebo (U.S.)
Various Solid Tumors
SoC with LSTA1 or placebo (U.S.)
Phase 2

Indication: Peritoneal Carcinomatosis (Colon & Ovarian)

LSTA1 + Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage (U.S.)
Peritoneal Carcinomatosis (Colon & Ovarian)
LSTA1 + Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage (U.S.)
Phase 1

Indication: Glioblastoma Multiforme

Temozolomide with LSTA1 or placebo (Estonia/Latvia)
Glioblastoma Multiforme
Temozolomide with LSTA1 or placebo (Estonia/Latvia)
Phase 2
LSTA1 received Fast Track and Orphan Drug Designations by the U.S. FDA in pancreatic ductal adenocarcinoma (PDAC) and Glioblastoma Multiforme (GBM), as well as U.S. FDA Rare Pediatric Disease Designation for Osteosarcoma